Methods for identifying inhibitors of mannan-binding lectin-associated serine protease (MASP) proteins and uses thereof
This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.
1. A method of screening for a small molecule capable of inhibiting MBL-associated serine protease (MASP) protein activity, the method comprising:
(a) contacting a purified MASP protein with a selected small molecule in the presence of a polypeptide comprising at least one collagen-like binding domain of a mannose-binding lectin (MBL) or ficolin and Ca 2+ , wherein the small molecule is selected based on the indicated capacity of the small molecule to disrupt the binding between at least one of residues Glu216, His218, Tyr225, Asp226, Asp263 and Ser265 of the CUB2 domain of the MASP protein (with reference to amino acid residues 166 to 276 of human MASP-1 set forth in SEQ ID NO:6), and MBL or ficolin, and wherein the MASP protein is selected from the group consisting of MASP-1, MASP-2 and MASP-3;
(b) determining the level of MASP protein activity of the MASP protein of step (a) in the presence of the small molecule, the peptide or ficolin and the Ca 2+ , wherein the level of the MASP protein activity is determined in a lectin pathway-specific assay by measuring lectin pathway-specific complement activation by the MASP protein;
(c) determining the level of the MASP protein activity in the absence of the small molecule by the lectin pathway-specific assay; and
(d) comparing the determined level of the MASP protein activity determined in step (b) with the level of the MASP protein activity determined in step (c),
wherein a reduced MASP protein activity determined in the presence of the small molecule according to step (b) as compared to the MASP protein activity determined in the absence of the small molecule according to step (c) indicates the capacity of the small molecule to inhibit MASP protein activity.
2. The method of claim 1 , wherein the small molecule that inhibits MASP protein activity disrupts the binding between at least one of the residues Glu216, Asp226, Asp263, and Ser265 of the MASP protein, and MBL or ficolin and Ca 2+ .
3. The method of claim 1 , wherein the small molecule comprises an NH 3 group.
4. The method of claim 1 , wherein the small molecule is a small amine.
5. The method of claim 1 , wherein the small molecule is a member selected from the group consisting of methylamine, ethylamine, lysine, dGMP—Deoxyguanosine monophosphate, dCMP—Deoxycytidine monophosphate, dAMP—Deoxyadenosine monophosphate, dTMP—Thymidine 5′-monophosphate, GMP—Guanosine monophosphate, AMP—Adenosine monophosphate, TMP—Thiamine monophosphate, UMP—Uridine monophosphate, dGTP—Deoxyguanosine triphosphate, dCTP—Deoxycytidine triphosphate, dATP—deoxyadenosine triphosphate, dTTP—Thymidine triphosphate, GTP—Guanosine triphosphate, CTP—Cytidine triphosphate, ATP—Adenosine Triphosphate, TTP—Thymidine triphosphate, and UTP—Uridine triphosphate.
6. The method of claim 1 , wherein the one or more small molecules have molecular weight(s) of less than 1,000 daltons.